Tang Capital Management LLC Takes Position in Atyr PHARMA INC (NASDAQ:ATYR)

Tang Capital Management LLC bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 671,134 shares of the company's stock, valued at approximately $2,430,000. Tang Capital Management LLC owned 0.80% of Atyr PHARMA at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Group One Trading LLC bought a new stake in shares of Atyr PHARMA during the fourth quarter valued at approximately $26,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at about $37,000. Raymond James Financial Inc. purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at about $39,000. Finally, XTX Topco Ltd bought a new stake in shares of Atyr PHARMA in the fourth quarter worth about $40,000. Institutional investors own 61.72% of the company's stock.

Atyr PHARMA Price Performance

ATYR traded up $0.26 during trading on Wednesday, reaching $3.75. The company's stock had a trading volume of 2,346,440 shares, compared to its average volume of 927,222. Atyr PHARMA INC has a 1 year low of $1.42 and a 1 year high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a market cap of $333.77 million, a price-to-earnings ratio of -3.99 and a beta of 0.79. The firm has a fifty day simple moving average of $3.25 and a two-hundred day simple moving average of $3.41.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. As a group, analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on ATYR. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Monday. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Finally, Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $18.60.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.